Schering has received marketing approval in three European countriesfor its Echovist ultrasound contrast agent. The German pharmaceutical firm, first to enter the world marketwith an MRI contrast agent, received approval for Echovist inFrance and Italy
Schering has received marketing approval in three European countriesfor its Echovist ultrasound contrast agent.
The German pharmaceutical firm, first to enter the world marketwith an MRI contrast agent, received approval for Echovist inFrance and Italy late last year. Approval in Germany was grantedduring the second quarter of 1991, according to Rainer von Mielecki,a spokesman for Schering in Berlin.
Von Mielecki responded in writing to SCAN's questions regardingSchering's ultrasound contrast development program.
Initial approvals of Echovist are for use in ultrasound imagingof blood flow in the right side of the heart. Schering is preparingapplications for expanded indications of Echovist, to be submittedto the first national authorities late this year, he said.
Company researchers have used the agent for imaging flow inthe left side of the heart and in blood vessels, including verysmall vessels such as the coronary arteries and tumor vessels.Schering is also investigating a gynecological use of Echovistto diagnose Fallopian tube patency, he said.
Echovist, like other ultrasound agents under development, relieson air bubbles to scatter the ultrasound signal and create thecontrast effect. Schering uses a suspension of galactose microparticlesto convey the air bubbles, which are formed on the surface ofthe sugar crystals, von Mielecki said.
The galactose microparticles dissolve and the free galactoseis metabolized with a half-life of 11 minutes. These galactose-basedagents avoid allergic side-effects encountered with use of MolecularBiosystem's albumin microspheres, he said. The agents are contraindicatedin patients with a history of galactosemia, a genetic disease.
The German contrast firm is developing a second product on thesame galactose technology. Schering is planning to develop Levovist,a transpulmonary agent, for use in both the U.S. and Japan. Echovistis not under active development in the U.S., he said.
Schering's agents have a shelf life of three years, becausethe galactose microparticles are stored as dry material and mixedinto suspension immediately before use, he said.
Schering estimates the world market for ultrasound contrastagents will reach DM 1 billion ($595 million) by the year 2000.Because there are many more ultrasound scanners than MRI systemsaround the world, the market potential for ultrasound agents islarger than for MRI contrast products.
This difference is smaller in the U.S., however, because ofa relatively large number of installed MRI systems, von Mieleckisaid.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Chest CT for Post-COVID-19 Abnormalities: Nine Takeaways from a Multi-Society Consensus Statement
July 22nd 2025Developed by 21 thoracic radiologists, the new international consensus statement addresses appropriate indications, scan acquisition and keys to reporting for the use of chest CT imaging in evaluating for residual lung abnormalities from COVID-19.